SCHEMBL38147012

SCHEMBL38147012

CC(C)(c1ccccc1)[C@H](NC(=O)c1ccc2cc(F)ccc2c1OCc1ccc(SC(F)(F)F)cc1)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 3/20 0.43
▸ KIFC1 Q9BW19 2/20 0.36
▸ KCNK2 O95069 2/20 0.36
▸ PDE2A O00408 3/20 0.33
▸ EPHX2 P34913 1/20 0.33
▸ NR1H4 Q96RI1 1/20 0.33
▸ PTPRZ1 P23471 1/20 0.33
▸ ITGB3 P05106 2/20 0.33
▸ ITGB1 P05556 2/20 0.33
▸ ITGAV P06756 2/20 0.33
▸ ITGA5 P08648 2/20 0.33
▸ LRRK2 Q5S007 1/20 0.33
▸ GPR34 Q9UPC5 1/20 0.33
▸ KCNK10 P57789 1/20 0.32
▸ PTPN2 P17706 1/20 0.32
▸ PTPN1 P18031 1/20 0.32
▸ PTPN7 P35236 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23461505 1.00 CXCR2 (0.43) CXCR2KIFC1KCNK2PDE2AEPHX2
SCHEMBL23461504 1.00 CXCR2 (0.43) CXCR2KIFC1KCNK2PDE2AEPHX2
SCHEMBL23460926 0.91 CXCR2 (0.43) CXCR2KCNK2PDE2AEPHX2NR1H4
SCHEMBL38666109 0.91 CXCR2 (0.43) CXCR2KCNK2PDE2AEPHX2NR1H4
SCHEMBL23460924 0.91 CXCR2 (0.43) CXCR2KCNK2PDE2AEPHX2NR1H4
SCHEMBL23461513 0.91 CXCR2 (0.52) CXCR2KIFC1KCNK2PDE2AEPHX2
SCHEMBL23461514 0.91 CXCR2 (0.52) CXCR2KIFC1KCNK2PDE2AEPHX2
SCHEMBL23461207 0.90 CXCR2 (0.42) CXCR2KIFC1KCNK2PDE2AEPHX2
SCHEMBL23461209 0.90 CXCR2 (0.42) CXCR2KIFC1KCNK2PDE2AEPHX2
SCHEMBL38664071 0.90 CXCR2 (0.42) CXCR2KIFC1KCNK2PDE2AEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630498-B2 Arylamides and methods of use thereof GENZYME CORPORATION (US) 2026-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630498-B2 Arylamides and methods of use thereof CFTR, CLIC1, CLCN2 CXCR2 63/4885KIFC1 3064/4885KCNK2 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback